Eligibility

ACTELION PHARMACEUTICALS, a Janssen Pharmaceutical Company of Johnson and Johnson, GRANT PORTAL
Actelion focuses on the discovery, development and commercialization of innovative treatments to serve critical, unmet medical needs. We strive on delivering ground-breaking medicines that improve patients' lives. We offer funding and support because we believe organizations are an important support network and source for raising awareness and providing education.

***As of October 15, 2020, CHARITABLE CONTRIBUTION APPLICATIONS ARE NO LONGER ACCEPTED THROUGH THIS PORTAL*** Please click here to request a Charitable Contribution applications. Thank you.

This portal no longer accepts SPONSORSHIP APPLICATIONS. Please contact Dana Roman at droman10@its.jnj.com regarding all Sponsorship Applications Thank you.

No live programming will be supported for the remainder of 2020. Virtual programs ONLY. Live programming will be considered once the pandemic restrictions are lifted in full.

What kind of grant requests will Actelion consider?
Actelion funds programs through unrestricted grants for educational purposes. Actelion will consider funding:

  • Independent Medical Education Programs - Actelion may provide funding for bona fide independent Continuing Medical Education (CME). These programs must be independent of Actelion influence with respect to content and design and must follow, where applicable, Food and Drug Administration (FDA), Office of Inspector General (OIG), and Accreditation Council for Continuing Medical Education (ACCME) guidelines.
  • Fellowships - Actelion may support organizations whose funds are used to support advanced study by clinical and research professionals at an accredited university or teaching institution.
  • What is the timeline requirement for submitting a grant to Actelion?
    Actelion requires that all grants are submitted at least 60 days in advance of the venue start date.

    What are Actelion US Educational Objectives?

    • Increase awareness of Pulmonary Arterial Hypertension (PAH) and associated diseases.
    • Increase awareness of the need for early recognition, diagnosis, and treatment of PAH.
    • Expand knowledge basis for the appropriate use of currently available PAH disease therapies.
    • Explore emerging science as it relates to improved diagnosis and treatment of PAH.

    What therapeutic areas will be considered by Actelion?
    Actelion supports legitimate, independent, bona fide educational programs related to PAH and other therapeutic areas and disease states consistent with the medical and research objectives developed by Actelion's Medical Affairs Department.

    Please be aware that multi-support is required in order to be eligible for consideration.

    Does your request fall within the guidelines listed above?